Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2016', provides in depth analysis on Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted pipeline therapeutics. The report provides comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects - The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Overview 7 Therapeutics Development 8 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Stage of Development 8 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Therapy Area 9 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Indication 10 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Products Glance 11 Early Stage Products 11 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Companies 12 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Products under Development by Universities/Institutes 14 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development 21 Aurigene Discovery Technologies Limited 21 Celgene Corporation 22 Trillium Therapeutics Inc. 23 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles 24 B-6H12 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 CC-90002 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease and Kidney Transplantation - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Peptide to Inhibit CD47 for Oncology - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Recombinant Proteins to Inhibit CD47 for Oncology - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecules to Inhibit CD47 for Oncology - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 TTI-508 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 TTI-621 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 TTI-622 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Projects 37 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Featured News & Press Releases 38 Jun 07, 2016: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress 38 May 18, 2016: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting 38 Apr 14, 2016: Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting 38 Mar 10, 2016: Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program 39 Feb 03, 2016: Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47 40 Dec 03, 2015: Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting 40 Sep 30, 2015: Trillium Therapeutics Provides Update on CD47 Program 41 Apr 16, 2015: Trillium To Provide Update On CD47 Program At The 2015 American Association For Cancer Research Annual Meeting 41 May 31, 2013: Engineered Molecules Boost Immune Attack On Cancer 42 Apr 04, 2012: Trillium Provides Update On Anti-CD47 Cancer Program 43 Dec 02, 2010: Trillium To Present Preliminary Results From Cancer Stem Cell Program At ASH Annual Meeting 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Aurigene Discovery Technologies Limited, H2 2016 21 Pipeline by Celgene Corporation, H2 2016 22 Pipeline by Trillium Therapeutics Inc., H2 2016 23 Dormant Projects, H2 2016 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
